COUR

A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes

A solid, uniform light blue color fills the entire image without any patterns, objects, or text visible.

Study Description

IRB #

20250893 WCG

NCT #

NCT06783309

Principal Investigator

Irl B. Hirsch, MD

Study Location

UW Medicine Diabetes Institute

This study is testing CNP-103, an investigational anitgen-specific immune tolerance therapy, for patients recently diagnosed with type 1 diabetes (T1D). The main goal of the trial is to evaluate if CNP-103 is safe and well-tolerated. Another goal is to determine if CNP-103 can help recently diagnosed patients retain some of their body’s own insulin-producing ability. Despite advances in insulin delivery and blood sugar monitoring, people with T1D still face significant health consequences related to the disease. Preserving pancreatic function and natural insulin production remains the optimal approach for managing T1D.

Study Details

FAQ COUR

Learn more about how you can contribute to important research by volunteering for COUR

Who Can Participate?

Ages between 12 and 35 years old

Have been diagnosed with Stage 3 type 1

Diabetes within the past 6 months (180 days)

Study Participation lasts about 13 months and will include at least 10 visits at the study center. If you are eligible, you will be randomly chosen to receive either CNP-103 or a placebo (an inactive substance). There is a 2 in 3 chance of receiving CNP-103. Neither you nor your study doctor will know which one you receive. The test drug (or placebo) will be given through the vein in your arm (intravenously, IV). During the study duration, the study team will monitor your health through check-ups and medical tests.

Compensation Provided

You will be paid for your time. If you complete all study visits, you will be paid $1000.00 (100$ per visit)

Contact Study Team

Interested? Complete form below to contact the study team!

Contact Name: Dori Khakpour

Phone Number: 206-945-4965

Email: dorik@uw.edu

Contact the Study Team - CNP-103

Name(Required)

First Last

Phone(Required)

Email(Required)

Enter Email Confirm Email

Comments(Required)

Preferred Method of Contact (email, phone call, text)